Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

A Phase 3 Multicenter, Prospective, Open-Label Efficacy and Safety Study of Immune Globulin (Human) 10% Caprylate/Chromatography Purified in Patients with Myasthenia Gravis Exacerbations.

Karelis G, Balasa R, De Bleecker JL, Stuchevskaya T, Villa A, Van Damme P, Lagrange E, Heckmann JM, Nicolle M, Vilciu C, Bril V, Mondou E, Griffin R, Chen J, Henriquez W, Garcia B, Camprubi S, Ayguasanosa J.

Eur Neurol. 2019 Oct 25:1-8. doi: 10.1159/000502818. [Epub ahead of print]

PMID:
31655810
2.

Peripheral neuropathy in HIV patients on antiretroviral therapy: Does it impact function?

Dudley MT, Borkum M, Basera W, Wearne N, Heckmann JM.

J Neurol Sci. 2019 Nov 15;406:116451. doi: 10.1016/j.jns.2019.116451. Epub 2019 Sep 6.

PMID:
31521960
3.

A review of the histopathological findings in myasthenia gravis: Clues to the pathogenesis of treatment-resistance in extraocular muscles.

Europa TA, Nel M, Heckmann JM.

Neuromuscul Disord. 2019 May;29(5):381-387. doi: 10.1016/j.nmd.2019.03.009. Epub 2019 Mar 26. Review.

PMID:
31029532
4.

C9orf72 repeat expansions in South Africans with amyotrophic lateral sclerosis.

Nel M, Agenbag GM, Henning F, Cross HM, Esterhuizen A, Heckmann JM.

J Neurol Sci. 2019 Jun 15;401:51-54. doi: 10.1016/j.jns.2019.04.026. Epub 2019 Apr 17.

PMID:
31009932
5.

Using Whole Genome Sequencing in an African Subphenotype of Myasthenia Gravis to Generate a Pathogenetic Hypothesis.

Nel M, Mulder N, Europa TA, Heckmann JM.

Front Genet. 2019 Mar 1;10:136. doi: 10.3389/fgene.2019.00136. eCollection 2019.

6.

Profiling of patient-specific myocytes identifies altered gene expression in the ophthalmoplegic subphenotype of myasthenia gravis.

Nel M, Prince S, Heckmann JM.

Orphanet J Rare Dis. 2019 Jan 29;14(1):24. doi: 10.1186/s13023-019-1003-y.

7.

Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial.

Wolfe GI, Kaminski HJ, Aban IB, Minisman G, Kuo HC, Marx A, Ströbel P, Mazia C, Oger J, Cea JG, Heckmann JM, Evoli A, Nix W, Ciafaloni E, Antonini G, Witoonpanich R, King JO, Beydoun SR, Chalk CH, Barboi AC, Amato AA, Shaibani AI, Katirji B, Lecky BRF, Buckley C, Vincent A, Dias-Tosta E, Yoshikawa H, Waddington-Cruz M, Pulley MT, Rivner MH, Kostera-Pruszczyk A, Pascuzzi RM, Jackson CE, Verschuuren JJGM, Massey JM, Kissel JT, Werneck LC, Benatar M, Barohn RJ, Tandan R, Mozaffar T, Silvestri NJ, Conwit R, Sonett JR, Jaretzki A 3rd, Newsom-Davis J, Cutter GR; MGTX Study Group.

Lancet Neurol. 2019 Mar;18(3):259-268. doi: 10.1016/S1474-4422(18)30392-2. Epub 2019 Jan 25.

PMID:
30692052
8.

Vibrotactile sensitivity of patients with HIV-related sensory neuropathy: An exploratory study.

Karpul D, McIntyre S, van Schaik A, Breen PP, Heckmann JM.

Brain Behav. 2019 Jan;9(1):e01184. doi: 10.1002/brb3.1184. Epub 2018 Dec 18.

9.

Exome sequencing identifies novel dysferlin mutation in a family with pauci-symptomatic heterozygous carriers.

Jalali-Sefid-Dashti M, Nel M, Heckmann JM, Gamieldien J.

BMC Med Genet. 2018 Jun 7;19(1):95. doi: 10.1186/s12881-018-0613-x.

10.

Myasthenic ophthalmoparesis: Time To resolution after initiating immune therapies.

Europa TA, Nel M, Heckmann JM.

Muscle Nerve. 2018 Oct;58(4):542-549. doi: 10.1002/mus.26172. Epub 2018 Aug 1.

PMID:
29790193
11.

The functionality of African-specific variants in the TGFB1 regulatory region and their potential role in HIVAN.

Nel M, Buys JM, Botha FCJ, Wearne N, Prince S, Heckmann JM.

Clin Exp Nephrol. 2018 Aug;22(4):764-772. doi: 10.1007/s10157-017-1516-4. Epub 2017 Dec 4.

PMID:
29204904
12.

A unique subphenotype of myasthenia gravis.

Heckmann JM, Nel M.

Ann N Y Acad Sci. 2018 Jan;1412(1):14-20. doi: 10.1111/nyas.13471. Epub 2017 Oct 6. Review.

PMID:
28984362
13.

High prevalence of "non-dipping" blood pressure and vascular stiffness in HIV-infected South Africans on antiretrovirals.

Borkum MS, Heckmann JM, Manning K, Dave JA, Levitt NS, Rayner BL, Wearne N.

PLoS One. 2017 Sep 20;12(9):e0185003. doi: 10.1371/journal.pone.0185003. eCollection 2017.

14.

Juvenile myasthenia gravis.

Heckmann JM.

Eur J Paediatr Neurol. 2017 Sep;21(5):696. doi: 10.1016/j.ejpn.2017.07.011. No abstract available.

PMID:
28784230
15.

Extraocular Muscle Findings in Myasthenia Gravis Associated Treatment-Resistant Ophthalmoplegia.

Rautenbach RM, Pillay K, Murray ADN, Heckmann JM.

J Neuroophthalmol. 2017 Dec;37(4):414-417. doi: 10.1097/WNO.0000000000000534.

PMID:
28742638
16.

Exome sequencing identifies targets in the treatment-resistant ophthalmoplegic subphenotype of myasthenia gravis.

Nel M, Jalali Sefid Dashti M, Gamieldien J, Heckmann JM.

Neuromuscul Disord. 2017 Sep;27(9):816-825. doi: 10.1016/j.nmd.2017.06.009. Epub 2017 Jun 21.

PMID:
28673556
17.

IgG-specific cell-based assay detects potentially pathogenic MuSK-Abs in seronegative MG.

Huda S, Waters P, Woodhall M, Leite MI, Jacobson L, De Rosa A, Maestri M, Ricciardi R, Heckmann JM, Maniaol A, Evoli A, Cossins J, Hilton-Jones D, Vincent A.

Neurol Neuroimmunol Neuroinflamm. 2017 Jun 5;4(4):e357. doi: 10.1212/NXI.0000000000000357. eCollection 2017 Jul.

18.

Evolution of sensory neuropathy after initiation of antiretroviral therapy.

Centner CM, Little F, Van Der Watt JJ, Vermaak JR, Dave JA, Levitt NS, Heckmann JM.

Muscle Nerve. 2018 Mar;57(3):371-379. doi: 10.1002/mus.25710. Epub 2017 Jul 6.

PMID:
28561925
19.

Letter re: A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis.

Heckmann JM, Bateman K.

Neurology. 2017 Jan 24;88(4):417. doi: 10.1212/WNL.0000000000003547. No abstract available.

PMID:
28115602
20.

Randomized Trial of Thymectomy in Myasthenia Gravis.

Wolfe GI, Kaminski HJ, Aban IB, Minisman G, Kuo HC, Marx A, Ströbel P, Mazia C, Oger J, Cea JG, Heckmann JM, Evoli A, Nix W, Ciafaloni E, Antonini G, Witoonpanich R, King JO, Beydoun SR, Chalk CH, Barboi AC, Amato AA, Shaibani AI, Katirji B, Lecky BR, Buckley C, Vincent A, Dias-Tosta E, Yoshikawa H, Waddington-Cruz M, Pulley MT, Rivner MH, Kostera-Pruszczyk A, Pascuzzi RM, Jackson CE, Garcia Ramos GS, Verschuuren JJ, Massey JM, Kissel JT, Werneck LC, Benatar M, Barohn RJ, Tandan R, Mozaffar T, Conwit R, Odenkirchen J, Sonett JR, Jaretzki A 3rd, Newsom-Davis J, Cutter GR; MGTX Study Group.

N Engl J Med. 2016 Aug 11;375(6):511-22. doi: 10.1056/NEJMoa1602489. Erratum in: N Engl J Med. 2017 May 25;376(21):2097. [Dosage error in article text].

21.

Characteristics Of acetylcholine-receptor-antibody-negative myasthenia gravis in a South African cohort.

Huda S, Woodhall MR, Vincent A, Heckmann JM.

Muscle Nerve. 2016 Dec;54(6):1023-1029. doi: 10.1002/mus.25154. Epub 2016 Oct 13.

PMID:
27105303
22.

Encephalopathy after persistent vomiting: Three cases of non-alcohol-related Wernicke's encephalopathy.

Antel K, Singh N, Chisholm B, Heckmann JM.

S Afr Med J. 2015 Jun;105(6):442-3.

PMID:
26716155
23.

The African-387 C>T TGFB1 variant is functional and associates with the ophthalmoplegic complication in juvenile myasthenia gravis.

Nel M, Buys JM, Rautenbach R, Mowla S, Prince S, Heckmann JM.

J Hum Genet. 2016 Apr;61(4):307-16. doi: 10.1038/jhg.2015.146. Epub 2015 Dec 3.

PMID:
26632886
24.

Myasthenia gravis is a rare but treatable disease.

Mombaur B, Heckmann JM.

S Afr Med J. 2015 Aug;105(8):619. No abstract available.

PMID:
26543935
25.

Isoniazid exposure and pyridoxine levels in human immunodeficiency virus associated distal sensory neuropathy.

van der Watt JJ, Benatar MG, Harrison TB, Carrara H, Heckmann JM.

Int J Tuberc Lung Dis. 2015 Nov;19(11):1312-9. doi: 10.5588/ijtld.15.0467.

PMID:
26467583
26.

Sensory neuropathy and metabolic risk factors in human immune deficiency virus infected South Africans receiving protease inhibitors.

Vermaak JR, Dave JA, Levitt N, Heckmann JM.

AIDS Res Ther. 2015 Sep 23;12:30. doi: 10.1186/s12981-015-0073-8. eCollection 2015.

27.

Limb-girdle weakness in a marfanoid man: distinguishing calpainopathy from Becker's muscular dystrophy.

Shaboodien G, Watkins DA, Pillay K, Beighton P, Heckmann JM, Mayosi BM.

Pract Neurol. 2015 Apr;15(2):152-4. doi: 10.1136/practneurol-2014-000992. Epub 2015 Jan 8. No abstract available.

PMID:
25573340
28.

Recommendations for the use of immunoglobulin therapy for immunomodulation and antibody replacement.

Peter JG, Heckmann JM, Novitzky N.

S Afr Med J. 2014 Sep 29;104(11):7306. doi: 10.7196/samj.8965.

PMID:
29183440
29.

Acute intermittent porphyria presenting as progressive muscular atrophy in a young black man.

Albertyn CH, Sonderup M, Bryer A, Corrigall A, Meissner P, Heckmann JM.

S Afr Med J. 2014 Apr;104(4):283-5.

PMID:
25118551
30.

Incidence of acetylcholine receptor-antibody-positive myasthenia gravis in South Africa.

Mombaur B, Lesosky MR, Liebenberg L, Vreede H, Heckmann JM.

Muscle Nerve. 2015 Apr;51(4):533-7. doi: 10.1002/mus.24348. Epub 2015 Feb 11.

PMID:
25060190
31.

The effects of prednisone and steroid-sparing agents on decay accelerating factor (CD55) expression: implications in myasthenia gravis.

Auret J, Abrahams A, Prince S, Heckmann JM.

Neuromuscul Disord. 2014 Jun;24(6):499-508. doi: 10.1016/j.nmd.2014.02.010. Epub 2014 Mar 6.

PMID:
24703255
32.

Plasma cytokine profiles in HIV-1 infected patients developing neuropathic symptoms shortly after commencing antiretroviral therapy: a case-control study.

Van der Watt JJ, Wilkinson KA, Wilkinson RJ, Heckmann JM.

BMC Infect Dis. 2014 Feb 10;14:71. doi: 10.1186/1471-2334-14-71.

33.

Sensory polyneuropathy in human immunodeficiency virus-infected patients receiving tuberculosis treatment.

Centner CM, Carrara H, Harrison TB, Benatar M, Heckmann JM.

Int J Tuberc Lung Dis. 2014 Jan;18(1):27-33. doi: 10.5588/ijtld.13.0375.

PMID:
24365548
34.

Molecular characterisation of virus in the brains of patients with measles inclusion body encephalitis (MIBE).

Hardie DR, Albertyn C, Heckmann JM, Smuts HE.

Virol J. 2013 Sep 12;10:283. doi: 10.1186/1743-422X-10-283.

35.

Mitochondrial genomics and antiretroviral therapy-associated metabolic complications in HIV-infected Black South Africans: a pilot study.

Sinxadi PZ, Dave JA, Samuels DC, Heckmann JM, Maartens G, Levitt NS, Wester CW, Haas DW, Hulgan T.

AIDS Res Hum Retroviruses. 2013 Jul;29(7):1031-9. doi: 10.1089/AID.2012.0373. Epub 2013 Mar 15.

36.

Manifestations of HIV infection in the peripheral nervous system.

Centner CM, Bateman KJ, Heckmann JM.

Lancet Neurol. 2013 Mar;12(3):295-309. doi: 10.1016/S1474-4422(13)70002-4. Review.

PMID:
23415569
37.

The characteristics of juvenile myasthenia gravis among South Africans.

Heckmann JM, Hansen P, Van Toorn R, Lubbe E, Janse van Rensburg E, Wilmshurst JM.

S Afr Med J. 2012 May 23;102(6):532-6.

PMID:
22668957
38.

The complexity of HIV vasculopathy.

Stanley A, Candy S, Levin C, Heckmann JM.

S Afr Med J. 2012 Mar 2;102(6):474-6.

PMID:
22668941
39.

Association of transforming growth factor β-1 (TGFB1) regulatory region polymorphisms with myasthenia gravis-related ophthalmoparesis.

Akinyi MV, Dandara C, Gamieldien J, Heckmann JM.

J Neuroimmunol. 2012 May 15;246(1-2):96-9. doi: 10.1016/j.jneuroim.2012.03.002. Epub 2012 Mar 27. Retraction in: J Neuroimmunol. 2014 Jun 15;271(1-2):69.

PMID:
22458981
40.

Silent casualties from the measles outbreak in South Africa.

Albertyn C, van der Plas H, Hardie D, Candy S, Tomoka T, Leepan EB, Heckmann JM.

S Afr Med J. 2011 May;101(5):313-4, 316-7. No abstract available.

PMID:
21837871
41.

A single-blinded trial of methotrexate versus azathioprine as steroid-sparing agents in generalized myasthenia gravis.

Heckmann JM, Rawoot A, Bateman K, Renison R, Badri M.

BMC Neurol. 2011 Aug 5;11:97. doi: 10.1186/1471-2377-11-97.

42.

Polyneuropathy, anti-tuberculosis treatment and the role of pyridoxine in the HIV/AIDS era: a systematic review.

van der Watt JJ, Harrison TB, Benatar M, Heckmann JM.

Int J Tuberc Lung Dis. 2011 Jun;15(6):722-8. doi: 10.5588/ijtld.10.0284. Epub 2011 Apr 7. Review.

PMID:
21477422
43.

Polymyositis in African HIV-infected subjects.

Heckmann JM, Pillay K, Hearn AP, Kenyon C.

Neuromuscul Disord. 2010 Nov;20(11):735-9. doi: 10.1016/j.nmd.2010.06.007. Epub 2010 Jul 13.

PMID:
20630756
44.

Beware of 'normal' creatine kinase levels in HIV-associated polymyositis.

Kenyon C, Pillay K, Heckmann JM.

S Afr Med J. 2010 Mar 8;100(3):156-7. No abstract available.

PMID:
20459937
45.

Myopathy with a normal creatine kinase level in juvenile myopathic dermatomyositis.

Ntusi NB, Heckmann JM.

S Afr Med J. 2010 Jan;100(1):24-5. No abstract available.

PMID:
20429482
46.

HIV neuropathy in South Africans: frequency, characteristics, and risk factors.

Maritz J, Benatar M, Dave JA, Harrison TB, Badri M, Levitt NS, Heckmann JM.

Muscle Nerve. 2010 May;41(5):599-606. doi: 10.1002/mus.21535.

PMID:
20229576
47.

A functional SNP in the regulatory region of the decay-accelerating factor gene associates with extraocular muscle pareses in myasthenia gravis.

Heckmann JM, Uwimpuhwe H, Ballo R, Kaur M, Bajic VB, Prince S.

Genes Immun. 2010 Jan;11(1):1-10. doi: 10.1038/gene.2009.61. Epub 2009 Aug 13.

48.

Opsoclonus-myoclonus syndrome and HIV-infection.

Scott KM, Parker F, Heckmann JM.

J Neurol Sci. 2009 Sep 15;284(1-2):192-5. doi: 10.1016/j.jns.2009.04.026. Epub 2009 May 5.

PMID:
19419738
49.

Primary central nervous system lymphoma: an unusual presentation.

Heckmann JM, O'Ryan S, Candy S.

S Afr Med J. 2008 Nov;98(11):851-2. No abstract available.

PMID:
19177889
50.

Predictive testing for Huntington disease in a developing country.

Futter MJ, Heckmann JM, Greenberg LJ.

Clin Genet. 2009 Jan;75(1):92-7. doi: 10.1111/j.1399-0004.2008.01044.x. Epub 2008 Jun 18.

PMID:
18565098

Supplemental Content

Loading ...
Support Center